Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilson H Miller

Showing results (91-100 of 168) with videos related to

Pageof 17
Sort By:
Oncogene|March 6, 2020
MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progressionWilliam Yang, Elie Khoury, Qianyu Guo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT IIGeorge R Blumenschein, Fadlo R Khuri, Joachim von Pawel, et al.
Investigational New Drugs|March 4, 2005
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancerMary J Mackenzie, Holger W Hirte, Goss Glenwood, et al.
Cell & Bioscience|February 4, 2024
Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironmentsMadelyn J Abraham, Christophe Goncalves, Paige McCallum, et al.
Molecular Pharmacology|January 17, 2014
The novel arsenical darinaparsin is transported by cystine importing systemsNicolas Garnier, Geneviève G J Redstone, Michael S Dahabieh, et al.
The Journal of Investigative Dermatology|January 24, 2015
The role of eIF4E in response and acquired resistance to vemurafenib in melanomaYao Zhan, Michael S Dahabieh, Arjuna Rajakumar, et al.
Journal of Inflammation (London, England)|November 6, 2025
Lack of phospho-eIF4E worsens experimental colitis by inhibiting Treg suppressive activityFrançois Santinon, Theodoros Papadopoulos, Meagan-Helen Henderson Berg, et al.
Molecular Cancer Therapeutics|October 22, 2020
Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase InhibitionTatiana Shorstova, Jie Su, Tiejun Zhao, et al.
Cell Death and Differentiation|July 22, 2017
Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosisMichael S Dahabieh, ZongYi Ha, Erminia Di Pietro, et al.
Frontiers in Pharmacology|February 15, 2013
Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML PatientTorsten H Nielsen, Nathalie Johnson, Nicolas Garnier, et al.
Pageof 17

Showing results (91-100 of 168) with videos related to

Sort By:
Pageof 17
Oncogene|March 6, 2020
MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progressionWilliam Yang, Elie Khoury, Qianyu Guo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT IIGeorge R Blumenschein, Fadlo R Khuri, Joachim von Pawel, et al.
Investigational New Drugs|March 4, 2005
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancerMary J Mackenzie, Holger W Hirte, Goss Glenwood, et al.
Cell & Bioscience|February 4, 2024
Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironmentsMadelyn J Abraham, Christophe Goncalves, Paige McCallum, et al.
Molecular Pharmacology|January 17, 2014
The novel arsenical darinaparsin is transported by cystine importing systemsNicolas Garnier, Geneviève G J Redstone, Michael S Dahabieh, et al.
The Journal of Investigative Dermatology|January 24, 2015
The role of eIF4E in response and acquired resistance to vemurafenib in melanomaYao Zhan, Michael S Dahabieh, Arjuna Rajakumar, et al.
Journal of Inflammation (London, England)|November 6, 2025
Lack of phospho-eIF4E worsens experimental colitis by inhibiting Treg suppressive activityFrançois Santinon, Theodoros Papadopoulos, Meagan-Helen Henderson Berg, et al.
Molecular Cancer Therapeutics|October 22, 2020
Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase InhibitionTatiana Shorstova, Jie Su, Tiejun Zhao, et al.
Cell Death and Differentiation|July 22, 2017
Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosisMichael S Dahabieh, ZongYi Ha, Erminia Di Pietro, et al.
Frontiers in Pharmacology|February 15, 2013
Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML PatientTorsten H Nielsen, Nathalie Johnson, Nicolas Garnier, et al.
Pageof 17